2016-08-31

RetroSense Therapeutics Receives Patent on Proprietary Method for Restoring Vision using Optogenetics

RetroSense Therapeutics, a privately-held, clinical-stage biopharmaceutical company, announced that the United States Patent and Trademark Office (USPTO) has granted U.S. patent Application No. 11/036,629, entitled “Method for Augmenting Vision in Persons Suffering from Photoreceptor Cell Degeneration.” RetroSense is the exclusive licensee of this intellectual property for augmenting vision from photoreceptor cell degeneration through a license with Massachusetts General Hospital. This patent broadly covers methods for restoring or improving vision using optogenetic approaches. The allowed claims cover the use of a broad range of opsins and rhodopsins in vision restoration.
Continue reading

Tokushima, Japan - 6 March 2024: Nichia, the world's largest LED manufacturer and inventor of the high-brightness blue and white LED, has started mass production of the new UV-B (308nm) and UV-A (330nm) LEDs in its popular 434 Series packa... READ MORE

New XLamp® S Line LEDs enhance growth, last longer, lower energy costs Horticulture and other forms of agricultural lighting require application-tuned ratios of spectral content, high efficacy and long lifetimes. Whether you are interested... READ MORE